Polycythemia Vera
📧 Sign up to get email alerts when something new happens for Polycythemia Vera.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]
Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including …
-
CLINICAL_TRIALS other · 2024-05-09Clinical Trial Update: Real-world Ruxolitinib Experience in PV
A clinical trial in Polycythemia Vera assesses real-world use of ruxolitinib; the study is currently NOT_YET_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
A completed prospective, non-interventional study evaluating JAKAVI (ruxolitinib) for Polycythemia Vera. Sponsor: Novartis Pharmaceuticals.
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]
A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unre…
-
FDA approval · 2024-04-29FDA Approved: BESREMI — Supplemental Application (PharmaEssentia USA)
The FDA approved a supplemental application for BESREMI (ropeginterferon alfa-2b) submitted by PharmaEssentia USA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders …
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit [Phase 2]
Phase 2 clinical trial update for PTG-300 in polycythemia vera with elevated hematocrit has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-11Clinical Trial Update: Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval [Phase 1]
Phase 1 trial assessing placebo-corrected QT/QTc effects of ITF2357 (Givinostat) at therapeutic and supratherapeutic doses alongside moxiflo…
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Myeloproliferative Neoplasms: an In-depth Case-control Study
A completed clinical trial examining myeloproliferative neoplasms with results posted; focuses on Polycythemia Vera, Essential Thrombocythem…
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Dual Vaccine Trial in Myeloproliferative Neoplasms [Phase 1, Phase 2]
A dual vaccine trial in myeloproliferative neoplasms completed Phase 1/2 testing for polycythemia vera and essential thrombocythemia.
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating LCL161 in patients with various forms of myelofibrosis has completed with results posted in 2023.
-
FDA approval · 2022-12-19FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
FDA approved a supplemental application for Jakafi (ruxolitinib) submitted by Incyte Corporation, resulting in an expanded/updated label und…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms [Phase 3]
A Phase 3 trial comparing low-dose interferon alpha with hydroxyurea in chronic myeloid neoplasms has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: A Phase 2 Study of RO7490677 In Participants With Myelofibrosis [Phase 2]
Phase 2 clinical trial update for RO7490677 in myeloproliferative neoplasms has completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate [NA]
Clinical trial update of imatinib mesylate for various myeloproliferative and related neoplasms including CMML, CML, polycythemia vera, hype…
-
FDA approval · 2021-11-12FDA Approved: BESREMI — Original Application (PharmaEssentia USA)
The FDA approved Besremi (ropeginterferon alfa-2b-nnqv) from PharmaEssentia USA for adults with polycythemia vera who require treatment, und…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. [Phase 3]
Phase 3 trial comparing ruxolitinib versus best available therapy in patients with polycythemia vera resistant or intolerant to hydroxyurea;…
-
CLINICAL_TRIALS trial_result · 2021-06-21Clinical Trial Update: PD-1 Inhibition in Advanced Myeloproliferative Neoplasms [Phase 2]
Phase 2 trial assessing PD-1 inhibition in advanced myeloproliferative neoplasms has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-01Clinical Trial Update: AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. [Phase 3]
Phase 3 trial comparing AOP2014 to BAT in Polycythemia Vera patients who previously participated in PROUD-PV has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera [Phase 2]
Phase 2 trial evaluating idasanutlin monotherapy in hydroxyurea-resistant/intolerant polycythemia vera; study terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 long-term safety and efficacy update for momelotinib in various myelofibrosis subtypes; study completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera [Phase 2]
Phase 2 trial update comparing KRT-232 to ruxolitinib in phlebotomy-dependent polycythemia vera is underway but status is unknown.
-
FDA approval · 2020-01-14FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
FDA approved a supplemental application for JAKAFI (ruxolitinib) submitted by Incyte Corporation, resulting in a label change and/or expande…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases [Phase 2]
Phase IIa study of HDAC inhibitor ITF2357 in JAK-2 V617F positive myeloproliferative diseases has completed with posted results.